Saturday 17 October 2026
Export RLAY’s income statement to Excel — free account
Relay Therapeutics, Inc.
RLAY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 95.4%, EPS was flat and free cash flow grew 2.13%, each against the same quarter a year earlier.
16.28
1.02
−5.90%
Follow RLAY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | — | 4 | — |
| (41.14%) | (41.12%) | (40.01%) | (36.77%) | ||
| (37.20%) | (37.05%) | (36.39%) | (33.72%) | ||
ROIC |
(1,812.63%) | (1,508.62%) | (157,022.78%) | 0.00% | |
Return on Tangible Assets |
(50.12%) | (49.87%) | (43.29%) | (32.57%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.44) | (1.37) | (1.19) | (1.05) | |
Free Cash Flow |
(248.87) | (235.86) | (213.36) | (212.20) | |
Capital Expenditures |
(0.41) | (0.41) | — | — | |
| Other line items | |||||
Cash ROIC |
(20.67%) | (21.03%) | (16.61%) | (11.78%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 1,030.61% | 1,406.36% | 2,455.31% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 223.60% | 266.95% | 454.04% | |
Share Based Compensation of Revenue |
0.00% | 246.11% | 292.19% | 438.15% | |
Operating CF/Net income |
0.83 | 0.85 | 0.78 | 0.74 | |
Depreciation/Fixed assets |
0.14 | 0.53 | 0.83 | (1.34) | |
Capex/Depreciation |
(1.28) | (0.45) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.15 | 0.10 | 0.05 | |
Operating CF per Share |
(1.44) | (1.37) | (1.19) | (1.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | 0.00 | 0.00 |
Columns are period end dates